Abeona Therapeutics receives Breakthrough Therapy designation status from FDA

Story excerpt provided by Crain’s Cleveland Business.

Abeona Therapeutics Inc. (Nasdaq: ABEO), a clinical-stage biopharmaceutical company, announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation status to the company’s EB-101 gene therapy technology for patients with Recessive Dystrophic Epidermolysis Bullosa, or RDEB.

The designation “enables collaborative discussions with senior FDA personnel, priority review and an expedited approval process to drug candidates where preliminary clinical trials indicate that a therapy may offer substantial treatment advantages over existing options for patients with serious or life-threatening diseases,” according to a news release from Abeona, which has offices in Cleveland, New York and Dallas.

Click here to read the complete article.

Originally published August 29, 2017.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: